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Abstract
The mineralocorticoid receptor (MR) belongs to the nuclear receptor superfam-
ily and regulates body fluid and electrolyte balance. In the last years, much effort 
has been put into the development of non-steroidal MR antagonists that overcome 
the side effects of the marketed steroid drugs, and can be used for the treatment 
of hypertension and heart failure, among others. Initially, MR was identified in 
epithelial cells, however it also plays important roles in non-epithelial tissues. 
In this sense, it is of interest to discover ligands that might induce different MR 
conformational changes, leading to specific coregulator interactions, which could 
confer tissue-specific effects. Different series of non-steroidal ligands with diverse 
central scaffolds has been described, which shows antihypertensive and cardiorenal 
protective effects. This review covers a description of different non-steroidal MR 
antagonist families, with special focus on compounds under clinical development. 
The analysis of the three-dimensional (3D) structures of non-steroidal MR antago-
nists in complex with the MR ligand-binding domain (LBD), recently reported, 
highlights the interactions crucial for binding. The structure-activity relationships 
of known ligands, together with the insights provided by the 3D structures of ligand 
- LBD MR complexes, could help in the development of non-steroidal MR antago-
nists with improved properties.
Keywords: mineralocorticoid receptor, MR antagonist, structure-activity 
relationship, clinical trials
1. Introduction
The mineralocorticoid receptor (MR) transduces the effects of the steroid 
hormone aldosterone on mineral ion homeostasis, extracellular volume, and blood 
pressure mainly by regulating kidney Na+ reabsorption and K+ and H+ excretion [1]. 
In addition, MR can also act as a high-affinity receptor for glucocorticoids. In aldo-
sterone target tissues such as the kidney distal nephron, glucocorticoid-mediated 
activation of MR is limited by co-expression of 11-β-hydroxysteroid dehydrogenase 
type II (11ßHSD2), which enzymatically limits access of glucocorticoids to the 
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receptor [2]. High corticosteroid circulating levels can overcome this mechanism, 
producing mineralocorticoid-like effects. Furthermore, MR tissue distribution is 
much broader than originally expected, and in many cells it is unclear if there are 
any mechanisms at all providing aldosterone selectivity over glucocorticoids [3]. It 
is thus reasonable to assume that both aldosterone and glucocorticoids can activate 
MR in a cell type-specific fashion.
The role of MR in blood pressure regulation and K+ homeostasis has been 
therapeutically exploited using steroid analogs with competitive inhibitory activity. 
This strategy is commonly used for treating primary aldosteronism and additional 
clinical situations where a decrease in extracellular volume is advantageous, such 
as essential hypertension and edema associated with congestive heart failure or 
cirrhosis [4]. The interest in MR antagonists has greatly increased in the past two 
decades. The unexpectedly broad tissue distribution of MR prompted research on 
possible additional physiological and pathological roles for this receptor [5]. It is 
now clear that MR has important contributions to the development of fibrosis [6], 
inflammation [7], and oxidative stress [8], greatly expanding the potential role 
of MR in human disease. Aldosterone/MR signaling associated with high NaCl 
intake produces cardiac, vascular, and renal injury independent of changes in blood 
pressure [9]. The benefits of MR antagonists in patients with heart failure resulted 
in the approval of their use to treat this condition [10]. Furthermore adipocyte MR 
activation may be implicated in obesity and metabolic syndrome, opening new pos-
sible applications to MR antagonists [11]. New roles of MR in ocular or skin diseases 
have led to new uses of MR antagonists [5, 12].
Unfortunately, therapeutic interventions aimed at limiting MR actions are 
hampered by adverse side effects. Ligand-binding domain (LBD) sequence conser-
vation between MR and glucocorticoid, progesterone, and androgen receptors (GR, 
PR, and AR) implies frequent ligand cross-reactivity. For instance, spironolactone 
is structurally related to progesterone and acts as a PR agonist and AR antagonist, 
leading to frequent adverse sexual side effects. This has largely been solved by the 
use of eplerenone, a second-generation MR antagonist with weaker affinity for AR 
and PR [13]. The use of MR antagonists is further complicated by their potassium-
sparing characteristics. While this activity is desirable in the context of hyperten-
sive patients treated with loop diuretics [14], it is associated with higher mortality 
in patients with heart failure [15]. Therefore, there is a clear need for developing 
selective MR modulators that preferably have a nonsteroidal nature and may pres-
ent selective beneficial actions without undesired side effects [4].
This review aims to delineate the different chemical structural families that 
have led to MR nonsteroidal antagonists. For a more comprehensive data regarding 
different compounds in each family, a recent review by Martin-Martinez et al. can 
be of interest [16]. In this chapter, we also focused on those compounds that entered 
clinical trials and in the known three-dimensional (3D) structure of nonsteroidal 
compounds bound to the LBD of MR.
2. Nonsteroidal MR ligands
An active search for nonsteroidal MR antagonists has been carried out to 
overcome the side effects observed with steroidal drugs. In general, starting from 
a high-throughput screening (HTS), an initial hit compound is identified. Next, 
a hit to lead optimization process, quite frequently through a structure-based 
design, leads to compounds with improved binding affinity and pharmacokinetic 
(PK) properties. Examples of different nonsteroidal MR antagonist families are 
included in this section. In addition, to facilitate a better understanding through the 
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manuscript, the 2D structures of compounds under clinical trials and/or known 3D 
structures are described in Sections 3 and 4.
The 1,4-dihydropyridine ring (DHP) has proven to be a rather interesting 
scaffold and have been explored by Pfizer, Bayer Pharma, and Merck (Figure 1). 
Their studies showed the importance of the stereochemistry at DHP C4 [17, 18], 
as well as a free DHP amino group [18, 19]. Pfizer described a series of DHP with 
a phenyl group at C4, with small, nonpolar substituents like F, Cl, or CF3 suit-
able at this ring [19]. Although a voluminous substituent at C2 led, in general, 
to lower affinity, the incorporation of tetrazolmethyl group as in 1 resulted in 
better physicochemical properties while maintaining potency and selectivity over 
other nuclear hormone receptors (NHRs, IC50 > 300 nM for PR, GR, and AR). 
Compound 1 reduces blood pressure and renal injury in rats. On the other hand, 
Bayer Pharma, starting from an HTS, and the subsequent optimization, identi-
fied DHP 2 (BR-4628) with a chromenone at DHP C4 as a potent MR antagonist 
with more that 150-fold selectivity over GR, AR and PR and a good PK profile 
in rats [18]. BR-4628 has been proposed to be a bulky antagonist with a passive 
mechanism. Docking studies shown that BR-4628 5-acetyl and C6-methyl groups 
protrude toward the MR helix H12. However, there is also a loss of contacts 
within this region compared to steroid agonist, which might account for the 
inability of this complex to recruit co-regulators [20]. Interestingly, for several 
steroid antagonists, a mechanism based on loss of contacts has been proposed 
with helix H12 leading to a destabilization of the AF2 region, which is involved in 
co-regulator interaction [21]. The moderate selectivity of BR-4628 versus L-type 
Ca2+ channels prevented further development. Afterwards, Bayer studies led to 
a series of heterobicyclic analogs, from which a naphthyridine derivative, named 
finerenone (17, see Figure 5), entered clinical trials. DHP has also been the focus 
of Merck, which patented a series of sub-micromolar binding affinity DHP, as 
derivative 3 [22].
Figure 1. 
DHP and five-membered heterocyclic rings as scaffolds in MR ligands. aCell-based assays. bCompetitive binding 
assays.
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Five-membered heterocyclic rings have also proven to be quite successful moieties 
in the search of nonsteroidal MR antagonists. In particular, the pyrrole ring is found 
in a series of MR ligands developed by Exelixis and Daiichi Sankyo, such as CS-3150 
that entered clinical trials (18, Figure 5) [23]. On the other hand, the pyrazoline ring 
has been explored by Pfizer, as in compound 4 (Figure 1), where the R enantiomer 
showed higher potency. Compound 4, with more than 500-fold selectivity over 
PR, and at least 2000-fold over GR and AR, behaves as an antagonist increasing the 
urinary Na+/K+ ratio in rats [24]. The 3-phenyl-pyrazoline cyclization led to a series of 
conformational restricted pyrazoline derivatives, one of them entered clinical trials, 
PF-3882845 (14, Figure 5) [25]. Additionally, starting from an HTS, Merck identi-
fied a series of MR antagonists based on the oxazolidine-2,4-dione scaffold. Several 
derivatives showed potent MR affinity, as compound 5 (Figure 1), which has signifi-
cant selectivity versus other NHRs (IC50, PR, AR, GR > 5 μm) [26].
On the other hand, it is worth mentioning the benzoxazinone-derived MR 
ligands, which have been also broadly explored. An analysis of the X-ray crystal 
structure of compounds with this bicycle bound to MR LBD provided insights 
regarding their binding determinants to MR, as explained below (Section 4). In 
general, in these series there is an additional aromatic ring linked to position 6 of the 
benzoxazinone moiety, either through linear linkers as in Novartis compound 6 [27] 
or heteroaromatic rings, like in Takeda derivatives 7, 19–22 (Figures 2 and 6) [28, 
29]. Compound 7 behaves as antagonist and shows good selectivity over GR, PR, and 
AR (IC50 > 2.5 μM). It is able to decrease urinary Na
+/K+ and has a blood pressure-
lowering effect similar to that of spironolactone in a DOCA-salt hypertensive rat 
model. Interestingly, a carbonyl linker led to AstraZeneca benzoxazinone derivative 
AZD9977, which is currently in clinical trials (15, Figure 5). In a recent publication, 
AstraZeneca describes the thorough structure and property studies that led to the 
identification of this clinical candidate [30]. Additionally, a benzoxazinone derivative 
with a rather different pattern of substituents was developed by Mitsubishi Tanabe 
Pharma leading to apararenone (16, Figure 5), which is also in clinical trials .
Figure 2. 
Benzoxazinone-, indole-, and indazole-derived MR ligands. aCell-based assays. bCompetitive binding assays.
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The indole group was also found as part of two series of potent MR antagonists 
identified by screening methodologies by Eli Lilly (Figure 2). One of them included 
a 3,3-bisaryloxoindol as central scaffold, where, for example, derivative 8 showed 
good selectivity over GR, PR, and AR (more than 390-fold) [31]. The other series 
contained an indole ring, as in compound 9, which was more potent than eplere-
none in lowering blood pressure in a rat hypertension model [32]. A related series 
containing an indazole ring and an aryl sulfonamide were developed by Merck 
Sharp & Dohme Corp., for example, compound 10 (stereochemistry not disclosed) 
that showed a good PK profile in rats [33].
Aryl sulfonamide and urea moieties were also found in compounds 11 and 
12, developed by Sumitomo Dainippon Pharma and Boehiringer Ingelheim, 
respectively (Figure 3) [34, 35]. Recently, a novel byaryl sulfonamide-based MR 
antagonist was identified in an HTS by AstraZeneca (compound 27, Figure 8). A 
combination of structure–activity relationship (SAR) exploration and X-ray crystal 
structure determination subsequently guided the design of related MR antagonist 
28 and 29 (Figure 8) [36].
Tricyclic scaffolds have also been studied, particularly those containing a 
central six- or seven-membered ring flanked by differently substituted phenyl 
moieties. These derivatives are frequently described within patents, and for some 
of them only scarce pharmacological data is available [16]. Thus, Eli Lilly has 
developed different families with interesting properties, among them the diben-
zooxepine 13 (Figure 4), an MR antagonist, with more than 800-fold selectivity 
over GR, AR, and PR. Compound 13 was studied in combination with tadalafil, a 
Figure 3. 
Aryl sulfonamide and urea functionalities in MR ligands. IC50 from competitive binding assays.
Figure 4. 
A tricyclic scaffold in MR antagonist. IC50 from competitive binding assays.
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Figure 6. 
2D and 3D structures of MR benzoxazine-3-one-based antagonist complexes. (A) 2D molecular structures. 
(B) Superimposition of the X-ray crystal structures of MR LBD in complex with aldosterone (in orange) and 
compound 19 (in yellow) (left) and compounds 19 (in yellow), 20 (in red), 21 (in pink), 22 (in blue), and 23 
(in cyan) (right) [75]. The hydrogen bonds and water molecules are depicted as yellow dashed lines and red 
spheres, respectively. IC50 from competitive binding assays.
Figure 5. 
MR antagonist that entered clinical trials. aCell-based assays. bBinding-based assays.
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mild vasodilator, for the treatment of patients with resistant hypertension. These 
studies showed that their combination led to a greater blood pressure reduction 
in patients than monotherapies [37]. Some websites associated this compound 
with LY2623091, which entered clinical trials [38, 39]. Recently, other tricyclic 
derivatives, with a seven-membered heterocyclic central ring and a benzoxazi-
none moiety linked to this ring, have been described by Vitae Pharmaceuticals. An 
example of these latter derivatives is compound 23 whose X-ray crystal structure 
bound to MR LBD has been solved (Figure 6) [40].
3. Nonsteroidal MR antagonists that entered clinical trials
The effort devoted to the search of nonsteroidal MR antagonist has led, to 
the best of our knowledge, to seven compounds entering clinical trials [41–43]. 
However, two of them, namely, LY2623091 from Eli Lilly and PF03882845 from 
Pfizer, have been discontinued. Both derivatives are nonsteroidal MR antagonist, 
selective, and oral bioavailable. LY262309 entered two phase II clinical studies, for  
patients with chronic kidney disease (CKD) or high blood pressure [44–46], 
but according to Adis Insight database, this compound was discontinued [47]. 
PF03882845 (14, Figure 5) entered phase I clinical studies in patients with type 2 
diabetic nephropathy; however the study terminated prematurely due to strategic 
reasons, according to Pfizer [48, 49].
Recently, AZD9977 from AstraZeneca and KBP-5074 from KBP Biosciences have 
entered clinical trials. AZD9977 (15, Figure 5) is a partial MR antagonist in vitro, with 
cardiorenal protection [50]. It separates organ-protective effects from urinary electro-
lyte excretion in rodent models, likely reducing hyperkalemia risk. This profile seems 
to be due to a different pattern of interactions with MR, particularly affecting Met777, 
which influences the AF2 surface. The AF2 region is key for co-regulator interaction, 
and a different recruitment compared to eplerenone was observed for this compound. 
Initial clinical studies showed that AZD9977 was safe and well tolerated; however, com-
pared with rodents, in humans the effects on urinary Na+/K+ were similar to eplerenone 
[51]. Yet four phase I clinical trials have been completed with this compound, all in 
the United Kingdom, the last ones in June 2018 [52]. On the other hand, KBP-5074 is a 
highly selective and potent MR antagonist. Phase I and IIa studies have been completed 
in the United States [53]. These studies evaluated safety, tolerability, and PK in healthy 
volunteers and patients with CKD or renal impairment. A phase IIb trial started in April 
2018 for patients with uncontrolled hypertension and advanced CKD.
To date, the most advanced compounds are esaxerenone (CS-3150), finerenone 
(BAY94-8862), and apararenone (MT-3995). Apararenone (16, Figure 5, Table 1) 
[42, 54, 55], developed by Mitsubishi Tanabe Pharma Corporation, has completed 
seven phase II clinical trials for the treatment of diabetic nephropathy; some studies 
include patients also with albuminuria or with albuminuria and moderately decreased 
in glomerular filtration rate. There is an active phase II clinical trial in patients with 
nonalcoholic steatohepatitis (NASH), which will be completed by April 2019.
Finerenone (17, Figure 5) is a potent, oral bioavailable MR antagonist from 
Bayer, with more than 500-fold selectivity over AR, PR, or GR [18]. Structural 
studies indicated that MR Ala773 and Ser810 are the reasons behind its selectiv-
ity. These studies also suggested that it is a bulky antagonist that inactivates MR 
producing a protrusion of LBD helix H12 and avoiding the recruitment of coactiva-
tors [56]. Furthermore, it has been found that finerenone modulates MR cofactor 
binding different from eplerenone. This selective modulation has been suggested 
as the molecular basis from the different clinical behavior of finerenone compared 
with eplerenone [57]. Interestingly, it behaves as an antagonist of S810L MR, a 
mutant that leads to a severe form of familiar hypertension. In preclinical models 
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finerenone showed better cardiorenal end-organ protection than spironolactone 
or eplerenone [58]. Its good properties prompted to further advance it to clinical 
trials (Table 2). In a phase II trial (mineralocorticoid receptor antagonist toler-
ability study (ARTS)) including subjects with chronic heart failure and mild or 
moderate CKD, finerenone was at least as effective as spironolactone in decreasing 
ventricular remodeling but with lower incidence of hyperkalemia and renal adverse 
effects [59, 60]. The fact that finerenone distributes equally between cardiac and 
renal tissues in rats, whereas spironolactone and eplerenone show a higher kidney 
NCT number Phase Enrollment Study start/
completion
Location
Efficacy and safety of finerenone in subjects with T2DM and DKD
NCT02540993
FIDELIO-DKD
III 4800 September 2015/
October 2019
Global
Efficacy and safety of finerenone in subjects with T2DM and the clinical diagnosis of DKD
NCT02545049
FIGARO-DKD
III 6400 September 2015/
February 2020
Global
Efficacy and safety of oral doses of BAY94-8862 in subjects with T2DM and the clinical diagnosis of diabetic 
nephropathy
NCT01874431
ARTS-DN
II 823 June 2013/August 
2014
Global
NCT01968668
ARTS-DN Japan
II 96 October 2013/
November 2014
Japan
Phase IIb safety and efficacy of different oral doses of BAY94-8862 in subjects with worsening chronic heart 
failure and left ventricular systolic dysfunction and either T2DM with or without CKD or CKD alone
NCT01807221
ARTS-HF
II 1058 June 2013/December 
2014
Global
NCT01955694
ARTS-HF-Japan
II 72 November 2013/
February 2015
Japan
BAY94–8862 dose finding trial in subjects with chronic heart failure and mild (part A) or moderate (part B) 
CKD
NCT01345656
ARTS
II 458 May 2011/July 2012 Global
Table 2. 
Finerenone (BAY94-8862) phase III and phase II ARTS clinical trials [68].
NCT number Phase Enrollment Study start/completion Location
Efficacy and safety of MT-3995 in patients with NASH
NCT02923154 II 40 September 2016/April 
2019
Japan
Efficacy and safety of MT-3995 in patients with diabetic nephropathy
NCT02517320 II 293 July 2015/January 2017 Japan
An extended treatment study of MT-3995 in patients with diabetic nephropathy
NCT02676401 II 241 February 2016/August 
2017a
Japan
aPrimary completion.
Table 1. 
Apararenone (MT-3995) phase II clinical trials completion after 2016 [55].
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accumulation, might explain the lower incidence of hyperkalemia. The lower 
accumulation, together with its minimal renal elimination, might open opportuni-
ties for the treatment of patients with renal impairment [61, 62]. A subsequent 
phase II study (ARTS-diabetic nephropathy (ARTS-DN)) analyzed the safety 
and efficacy of finerenone in subjects with type 2 diabetes mellitus (T2DM) and 
diabetic nephropathy. In this study the urinary albumin to creatinine ratio (UACR) 
decreased in patients treated with finerenone compared to placebo, with no signifi-
cant differences in adverse effects observed between both groups [63, 64]. In the 
ARTS-heart failure trial (ARTS-HF), different doses of finerenone and eplerenone 
were compared for patients with worsening heart failure with concomitant T2DM 
and/or CKD. Finerenone (10–20 mg dose) showed better outcome, including death, 
cardiovascular hospitalization, or emergency visit [65]. There are two large trials on 
going (FIDELIO-DKD, FIGARO-DKD) including subjects with T2DM and diabetic 
kidney disease (DKD) at doses of 10 or 20 mg of finerenone.
Recently, the administration of finerenone to a rat model of metabolic syndrome 
(Zucker fa/fa) showed that finerenone exerted cardiac protection, as it has been 
previously described for spironolactone. However, only finerenone afforded renal 
protection [66, 67].
Esaxerenone (18, Figure 5) is a highly potent and selective MR antagonist, with 
at least 1000-fold higher selectivity over AR, PR, or GR. It has also long-lasting oral 
activity, longer than steroidal drugs [23]. In addition, it has shown antihypertensive 
and cardiorenal protective effects in Dahl salt-sensitive hypertensive rats with 
superior potency than spironolactone or eplerenone and no apparent hyperkalemia 
[69]. The similar balanced distribution of esaxerenone to the kidney and heart in 
rats might be the reason of its higher organ-protective effects than marketed drugs. 
A subsequent study was performed with a model of hypertensive rats, based on a 
synthetic mineralocorticoid, deoxycorticosterone acetate (DOCA), that induces 
hypertension and renal injury in combination with salt loading (DOCA rats). In this 
model, esaxerenone was able to prevent hypertension and the development of renal 
damage. It has also been suggested that its beneficial actions on renal injury cannot 
NCT number Phase Enrollment Study start/
completion
Location
Study of CS-3150 in patients with severe hypertension
NCT02808026 III 20 June 2016/February 
2017
Japan
Study of CS-3150 in hypertensive patients with type 2 diabetes and albuminuria
NCT02807974 III 51 June 2016/March 
2017
Japan
Study of CS-3150 in combination with ARB or ACE inhibitor in hypertensive patients with moderate renal 
impairment
NCT02807987 III 58 June 2016/May 2017 Japan
Long-term study of CS-3150 as monotherapy or in combination with other antihypertensive drug in Japanese 
patients with essential hypertension
NCT02722265 III 368 March 2016/July, 
2017
Japan
Study of CS-3150 in patients with essential hypertension
NCT02890173
ESAX-HTN
III 1001 September 2016/July, 
2017
Japan
Table 3. 
Esaxerenone (CS-3150) phase III clinical trials [72].
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be only attributed to its antihypertensive effect but also to direct renal protection 
through antifibrotic, anti-inflammatory, and antioxidant actions. Interestingly, this 
compound is also able to restore the established renal damage in DOCA rats [70]. 
Esaxerenone was identified by Exelixis’ research collaboration with Daiichi Sankyo. 
In 2006 they signed an agreement in which Daiichi Sankyo was granted a worldwide 
license. To date, five phase III studies have been completed related to hypertension, 
some of them in addition to type 2 diabetes and albuminuria or moderate renal 
impairment. The combination with other antihypertensive therapies has also been 
studied (Table 3). In February 2018, Exelixis announced that Daiichi Sankyo had sub-
mitted a regulatory application to the Japanese Pharmaceutical and Medical Devices 
Agency for esaxerenone to be approved for the treatment of hypertension [71].
4.  Structural determinants for nonsteroidal MR antagonists  
binding to MR LBD
To the best of our knowledge, to date 12 X-ray crystal structures of nonsteroidal 
ligands bound to MR LBD have been solved. Nine of these reported structures 
correspond to MR antagonists within the benzoxazinone moiety derivatives class 
(Figures 6A and 7A) (PDB IDs: compound 15, 1.82 Å 5MWP [50]; 19, 1.35 Å 3VHV 
[28]; 20, 2.05 Å 2WFF [29]; 21, 1.40 Å 3WFG [29]; 22, 1.10 Å 4PF3 [73]; 23, 2.5 Å 
5HCV [40]; 24, 1.54 Å 6GEV [30]; 25, 1.8 Å 6GG8 [30]; and 26, 1.71 Å 6GGG [30]), 
whereas the remaining three correspond to a sulfonamide aryl moiety (PDB IDs: 27, 
1.86 Å 5L7E; 28, 2.01 Å 5L7G; and 29, 2.12 Å 5L7H) (Figure 8A) [36].
The X-ray crystal structure of MRC808S/S810L-LBD double mutant in complex with 
compound 19 first revealed the binding mode of benzoxazine-3-one derivatives. 
The NH group and the carbonyl oxygen of this moiety form hydrogen bonds to 
Asn770. In addition, the nitrogen atoms of the triazole scaffold establish hydrogen 
bonds to residue Gln776 and through a water molecule to Arg817 (Figure 6B). 
Similarly, aldosterone, the main MR hormone, is also engaged in hydrogen bonding 
with both Gln776 and Arg817 through its C3-ketone moiety, as well as with Asn770 
through its C21-hydroxyl group (Figure 6) [74].
On the other hand, compound 20, which was reported later [29], also forms 
hydrogen bonds to Asn770 through the NH group and the carbonyl oxygen of 
benzoxazine as described for compound 19. In addition, compound 20 forms a new 
hydrogen bond to Thr945 through the carbonyl oxygen of the benzoxazine-3-one 
moiety (Figure 6B). The carbonyl oxygen in the dihydrofuran-2-one scaffold estab-
lishes hydrogen bonds to residues Arg817 and Gln776 through a water molecule. 
Overall, compound 20 binds to MR LBD in a similar way as compound 19. Based 
on these structural considerations, compound 21, a dihydrofuran-2-one derivative, 
was subsequently developed. As expected, the binding mode of compound 21 was 
similar to that of compounds 19 and 20 (Figure 6B).
Later, compound 22, a benzoxazine-3-one derivative with an azole central ring as 
core scaffold, was developed [73]. This molecule is a highly potent MR antagonist and 
also shows remarkable selectivity over other steroid hormone receptors. In addition, it 
exhibits good PK profile and very low partial agonistic activity [3]. The azole central 
ring of compound 22 was selected to avoid the formation of water-mediated hydro-
gen bonding networks, which is known to contribute to partial agonistic activity of 
some previously reported benzoxazine-3-one derivatives [29, 73]. As expected, the 
binding mode of compound 22 is similar to that of compounds 19–21, as observed 
by the solution of the X-ray crystal structure of its complex with MR LBD (PDB ID: 
4PF3) (Figure 6B). The NH group and the carbonyl oxygen of the benzoxazine-3-one 
moiety form hydrogen bonds to Asn770 and Thr945, and the 4-fluorobenzene ring 
11
Advances in the Development of Non-Steroidal Mineralocorticoid-Receptor Antagonists
DOI: http://dx.doi.org/10.5772/intechopen.88417
occupies the α-face hydrophobic pocket. The ligand 2,2-difluoropropyl-3-hydroxy 
moiety points out toward the residues Gln776 and Arg817. Its hydroxyl group directly 
forms a hydrogen bond to Gln776. The two fluorine atoms do not form any specific 
hydrogen bonding interactions suggesting that the major contribution of these 
fluorine atoms to the binding is hydrophobic.
In 2016, Vitae Pharmaceuticals developed compound 23, a benzoxazine-3-one 
derivative with a tricyclic scaffold. The X-ray crystal structure of compound 23 in 
complex with MR LBD showed again a binding mode similar to compounds 19–22. 
Similarly, the benzoxazinone moiety is engaged in three hydrogen bonds, two with 
Asn770, through its NH and CO groups, and another one with Thr945 through 
its carbonyl oxygen (Figure 6B). The tricyclic structure does not engage in any 
hydrogen bonding with MR LBD [40].
Recently, compound 15 (AZD9977) has been identified as a novel and selective 
benzoxazine-3-one-based partial MR antagonist [50]. The X-ray crystal structure of 
compound 15 in complex with MRC808S/C910S-LBD double mutant revealed the molec-
ular determinants of its high affinity and selectivity for MR (5MWP). Likewise, 
compound 15 benzoxamide moiety is also involved in hydrogen bonds with Asn770 
and Thr945, whereas compound 15’s amide extension forms hydrogen bonds with 
Figure 7. 
2D and 3D structures of AstraZeneca benzoxazine-3-one-based antagonist complexes. (A) 2D molecular 
structures. (B) Superimposition of the X-ray crystal structures of MR LBD bound to compounds 15 (in cyan), 
24 (in red), and 25 (in light yellow) on the left and 15 (in cyan), 24 (in red), 25 (in light yellow), and 26 (in 
purple) on the right [30, 50]. The hydrogen bonds and water molecules are depicted as yellow dashed lines and 
red spheres, respectively. Ki from competitive binding assays.
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Gln776, Arg817, and Ser810 (Figure 6B). An ordered water molecule is also found 
in the ligand-binding pocket, but it does not seem to mediate hydrogen binding 
between this compound and MR LBD. The 3,4-dihydro-2H-1,4-benzoxazine oxygen 
interacts through hydrogen bonding with Ser811. Within the steroid receptor family, 
Ser811 is unique to MR, which might contribute to the selectivity of compound 15. 
The identification of 15 was guided by structure-based design, and in this process 
three X-ray structures were solved, namely, those of MR LBD bound to derivatives 
24, 25, and 26. As it is shown in Figure 7, the binding mode of these compounds is 
rather similar. However, as expected, derivative 24 is not able to interact with Gln776 
or Arg817. On the other hand, the isobutyl substituent of 26 causes a rearrangement 
resulting in an extension of helix H7 and a reposition of helix H6 [30].
Regarding the sulfonamide aryl-based nonsteroidal MR antagonists, in 2017, 
Nordqvist et al. solved the first X-ray crystal structure of this scaffold-containing 
derivatives through hit compound 27 in complex with MR LBD (PDB ID: 5L7E) 
[36]. The 3D structure revealed that the isoxazole is located close to residues Gln776 
and Arg817 (Figure 8). On the other side of the ligand-binding pocket, compound 
27’s sulfonamide NH also interacts directly with Asn770 through hydrogen bond-
ing. One of the sulfonamide oxygen atoms interacts with both Asn770 and Thr945 
through water-mediated hydrogen bond. Interestingly, compound 27 folds back 
upon itself, pivoting on the sulfonamide motif, to form an intramolecular pack-
ing interaction between the two phenyl moieties acquiring a U-shaped binding 
mode. Following the superimposition of its X-ray crystal structure and that of 
Figure 8. 
2D and 3D structures of MR sulfonamide aryl-based antagonist complexes. (A) 2D molecular structures. 
Superimposition of the X-ray crystal structures of MR LBD in complex with (B) compounds 27 (in orange), 
28 (in magenta), and 29 (in yellow), (C) compounds 27 and 28, and (D) compounds 27 and 29 [75]. The 
hydrogen bonds and water molecules are depicted as yellow dashed lines and red spheres, respectively. IC50 from 
human MR reporter gene assays.
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compound 21 (3WFG), it was reasoned to expand the ligand from the isoxazole 
5-methyl substituent toward the area around Met852 which is occupied by a phenyl 
ring of compound 21. Thus, compound 28 was developed with increased binding 
affinity toward MR and selectivity over PR and GR. The X-ray crystal structure of 
MR LBD and compound 28 complex (5L7G) verified that the proposed isoxazole 
orientation of hit compound 27 was retained and the side chain of Met852 moved 
to accommodate the 2,3-difluorophenoxymethyl moiety (Figure 8C). Afterwards, 
a deeper analysis of ligand binding modes inspired the design of compound 29, the 
first potent macrocyclic oxosteroid receptor antagonist. Despite the conformation 
constraints imposed by the macrocyclization, the X-ray crystal structure of the 
complex between MR LBD and compound 29 (5L7H [36]) disclosed that the ligand 
interactions to the receptor stayed the same as those exhibited by compounds 27 
and 28 (Figure 8D). It is worth noting that the water molecule mediating hydro-
gen bond between compounds 27–29 and Ans770 and Thr945 is displaced by the 
benzoxazine scaffold in compounds 15 and 19–25 (Figures 6 and 7). For these latter 
compounds, the benzoxazine scaffold forms a bidentate hydrogen bonding with 
Asn770 and an additional hydrogen bond with Thr945.
5. Conclusions
Since 1959 in which the steroid MR antagonist spironolactone was introduced 
in the market [42], continuous research has been carried out in attempting to 
overcome the undesired side effects of this drug. Eplerenone, a second-generation 
MR antagonist, although more selective for MR, still increases the incidence of 
hyperkalemia. For this reason, the research was turned toward a third generation 
of compounds, comprising nonsteroidal antagonists within different chemotypes, 
which show in general lower side effects. Several examples of this third generation 
have entered clinical trials as compiled in this review. However, in spite of the last 
decades of advances, there are still important questions that need further research. 
Thus, for example, the structural requirements needed for ligands to discriminate 
the recruitment of different co-regulators and, hence, to fine-tune the transcription 
of selected genes are still poorly understood. Undoubtedly, a larger body of knowl-
edge in this field will contribute significantly to the future development of novel 
MR antagonists with improved properties.
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